Risk factors for hepatitis C recurrence after liver transplantation

Journal of Viral Hepatitis

Volumn 14, Issue SUPPL. 1, 2007, Pages 89-96

  Roche, B ^b   Samuel, D ^a  

^a HÔPITAL PAUL BROUSSE   (France)

^b NONE

Author keywords

Hepatitis C; Immunosuppression; Liver transplantation; Recurrence

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; TACROLIMUS;

CLINICAL TRIAL; CONFERENCE PAPER; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DISEASE SEVERITY; FOLLOW UP; HEPATITIS C; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; PRIORITY JOURNAL; RECURRENT INFECTION; RISK FACTOR; SURVIVAL RATE; VIRUS LOAD;

HEPATITIS C; HUMANS; LIVER TRANSPLANTATION; RECURRENCE; RISK FACTORS;

EID: 35448971041     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2007.00920.x     Document Type: Conference Paper

References (69)

1. Berenguer M., Prieto M, Rayon JM et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000 32: 852 858.
2. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002 122: 889 896.
3. Berenguer M, Prieto M, Cordoba J et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J Hepatol 1998 28: 756 763.
4. Berenguer M, Prieto M, San Juan F et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002 36: 202 210.
5. Garcia-Retortillo M, Forns X, Feliu A et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002 35: 680 687.
6. Powers KA, Ribeiro R, Patel K et al. Kinetics of hepatitis C virus reinfection after liver transplantation. Liver Transpl 2006 12: 207 216.
7. Dahari H, Feliu A, Garcia-Retortillo M, Forns X, Neumann A. Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation. J Hepatol 2005 42: 491 498.
8. Di Martino V, Saurini F, Samuel D et al. Long-term longitudinal study of intrahepatic hepatitis C virus replication after liver transplantation. Hepatology 1997 26: 1343 1350.
9. Wright TL, Donegan E, Hsu H et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992 103: 317 322.
10. Neumann UP, Berg T, Bahra M et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004 41: 830 836.
11. Berenguer M, Aguilera V, Prieto M et al. Delayed onset of severe hepatitis C-related liver damage following liver transplantation: a matter of concern? Liver Transpl 2003 9: 1152 1158.
12. McCaughan GW, Zekry A. Mechanisms of HCV reinfection and allograft damage after liver transplantation. J Hepatol 2004 40: 368 374.
13. Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation? J Hepatol 2005 42: 448 456.
14. Berenguer M, Ferrell L, Watson J et al. HCV-related fibrosis progression following liver transplantation increase in recent years. J Hepatol 2000 32: 673 684.
15. Berenguer M, Crippin J, Gish R et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003 38: 34 41.
16. Belli LS, Burroughs A, Burra P et al. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl 2007 13: 733 740.
17. Thuluvath PJ, Krok KL, Segev DL, Yoo HY. Trends in post-liver transplant survival in patients with hepatitis C between 1991 and 2001 in the United States. Liver Transpl 2007 13: 719 724.
18. Samuel D, Forns X, Berenguer M et al. Report of the monothematic EASL conference on liver transplantation for viral hepatitis. J Hepatol 2006 45: 127 143.
19. Feray C, Gigou M, Samuel D et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995 108: 1088 1096.
20. Feray C, Caccamo L, Alexander GJM et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. Gastroenterology 1999 117: 619 625.
21. Ghobrial RM, Farmer D, Baquerizo A et al. Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression and causes of retransplantation during an 8-year single-center experience. Ann Surg 1999 229: 824 831.
22. Zekry A, Whiting P, Crawford D et al. Liver transplantation for HCV-associated liver cirrhosis: predictors of outcomes in a population with significant genotype 3 and 4 distribution. Liver Transpl 2003 9: 339 347.
23. Vargas HE, Laskus T, Wang L et al. The influence of hepatitis C virus genotypes on the outcome of liver transplantation. Liver Transpl Surg 1998 4: 22 27.
24. Di Martino V, Brenot C, Samuel D et al. Influence of liver hepatitis C virus RNA and hepatitis C virus genotype on FAS-mediated apoptosis after liver transplantation for hepatitis C. Transplantation 2000 70: 1390 1396.
25. Charlton M, Seaberg E, Wiesner R et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998 28: 823 830.
26. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000 32: 1125 1130.
27. Doughty A, Painter D, McCaughan G. Post-transplant quasispecies pattern remains stable over time in patients with recurrent cholestatic hepatitis due to hepatitis C virus. J Hepatol 2000 32: 126 134.
28. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002 51: 248 252.
29. Rifai K, Sebagh M, Karam V et al. Donor age influences 10-year liver graft histology independently of hepatitis C virus infection. J Hepatol 2004 41: 446 453.
30. Garcia-Retortillo M, Forns X, Llovet JM et al. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004 40: 699 707.
31. Shiffman M, Stravitz R, Contos M et al. Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. Liver Transpl 2004 10: 1248 1255.
32. Guo L, Orrego M, Rodriguez-Luna H et al. Living donor liver transplantation for hepatitis C-related cirrhosis: no difference in histological recurrence when compared to deceased donor liver transplant recipients. Liver Transpl 2006 12: 516 519.
33. Schmeding M, Neumann U, Puhl G, Bahra M, Neuhaus R, Neuhaus P. Hepatitis C recurrence and fibrosis progression are not increased after living donor liver transplantation: a single-center study of 289 patients. Liver Transpl 2007 13: 687 692.
34. Pelletier S, Raymond D, Crabtree T et al. Hepatitis C-induced hepatic allograft injury is associated with a pretransplantation elevated viral replication rate. Hepatology 2000 32: 418 426.
35. Toniutto P, Fabris C, Bortolotti N et al. Evaluation of donor hepatic iron concentration as a factor of early fibrotic progression after liver transplantation. J Hepatol 2004 41: 307 311.
36. Rosen H, Hinrichs D, Gretch D et al. Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation. Gastroenterology 1999 117: 926 932.
37. Belli L, Burra P, Poli F et al. HLA-DRB1 donor-recipient mismatch affects the outcome of hepatitis C disease recurrence after liver transplantation. Gastroenterology 2006 130: 695 702.
38. Prieto M, Berenguer M, Rayon JM et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999 29: 250 256.
39. Sheiner PA, Schwartz ME, Mor E et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995 21: 30 34.
40. Lake JR. The role of immunosuppression in recurrence of hepatitis C. Liver Transpl 2003 9: S63 S66.
41. Wiesner RH. A long-term comparison of tacrolimus (FK 506) versus cyclosporine in liver transplantation: a report of the United States FK 506 study group. Transplantation 1998 66: 493 499.
42. Martin P, Busuttil R, Goldstein R et al. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl 2004 10: 1258 1262.
43. Samonakis DN, Triantos C, Thalheimer U et al. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl 2005 11: 386 395.
44. Zervos X, Weppler D, Fragulidis G et al. Comparison of tacrolimus with neoral as primary immunosuppression in hepatitis C patients after liver transplantation. Transplant Proc 1998 4: 1405 1406.
45. Berenguer M, Aguilera V, Prieto M et al. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients. Liver Transpl 2006 12: 762 767.
46. Levy G, Grazi G, San Juan F et al. 12-months follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIST2) comparing cyclosporine micoemulsion (C2 monitoring) and tacrolimus. Liver Transpl 2006 12: 1464 1472.
47. Berenguer M, Rovuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007 13: 21 29.
48. Nakagawa M, Sakamoto N, Enomoto N et al. Specific inhibition of hepatitis C virus replication by cyclosporine A. Biochem Biophys Res Commun 2004 313: 42 47.
49. Firpi R, Zhu H, Morelli G et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl 2006 12: 51 57.
50. Watashi K, Hijikata M, Hosaka M, Yamagi M, Shimotohno K. Cyclosporine A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003 38: 1282 1288.
51. Henry SD, Metselaar H, Lonsdale R et al. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-α. Gastroenterology 2006 131: 1452 1462.
52. Wiesner R, Rabkin J, Kintmalm G et al. A randomized double-blind comparative study of mycophenolate mofetil and aziathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001 7: 442 450.
53. Jain A, Kashyap R, Demetris A, Eghstesad B, Pokharna R, Fung JJ. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl 2002 8: 40 46.
54. Barha M, Neumann U, Jacob D et al. MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course. Am J Transplant 2005 5: 406 411.
55. Zekry A, Gleeson M, Guney S, McCaughan G. A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection. Liver Transpl 2004 10: 52 57.
56. Fasola C, Netto G, Christensen L, Rakela J, Thomas M. Lower incidence of early HCV RNA levels and HCV recurrence post-liver transplantation in patients induced with mycophenolate mofetil: a high-dose benefit. Am J Transplant 2002 2: 196.
57. Nelson D, Soldevila-Pico C, Reed A et al. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl 2001 12: 1064 1070.
58. Calmus Y, Scheele J, Gonzalez-Pinto I et al. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containig triple therapy in liver transplant recipients. Liver Transpl 2002 8: 123 131.
59. Berenguer M, Aguilera V, Prieto M et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 2006 44: 717 722.
60. Burak KW, Kremers W, Batts K et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002 8: 362 369.
61. Humar A, Kumar D, Raboud J et al. Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation. Am J Transplant 2002 2: 461 466.
62. Watt KD, Lyden E, Gulizia J, McCashland T. Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome. Liver Transpl 2006 12: 134 139.
63. Baron PW, Sindram D, Higdon D et al. Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C after liver transplantation. Liver Transpl 2000 6: 407 412.
64. Testa G, Crippin J, Netto G et al. Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients. Liver Transpl 2000 6: 553 561.
65. Russo M, Firpi R, Nelson D, Schoonhoven R, Shrestha R, Fried M. Early stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis C. Liver Transpl 2005 11: 1235 1241.
66. Gawrieh S, Papouchado B, Burgart L, Kobayashi S, Charlton M, Gores G. Early hepatic stellate cell activation predicts severe hepatitis C recurrence after liver transplantation. Liver Transpl 2005 11: 1207 1213.
67. Blasco A, Forns X, Carrion J et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 2006 43: 492 499.
68. Carrion J, Navasa M, Garcia-Retortillo M et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007 132: 1746 1756.
69. Charlton M, Ruppert K, Belle S et al. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transpl 2004 10: 1120 1130.